The following statement has been released with regard to the Cost-Effectiveness of Treatment section currently in development:

 

 

HCVguidelines.org, a website developed by the American Association of the Study for Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) in collaboration with International Antiviral Society-USA (IAS-USA) to provide up-to-date guidance on the treatment of hepatitis C (HCV), will be updated with a section on cost-effectiveness of treatment. The recent availability of new, direct-acting antivirals for the treatment of hepatitis C (HCV) offers the prospect of cure for the great majority of patients with HCV. The high costs of these new therapies have been the subject of much discussion, and IDSA and AASLD are concerned that the pricing of these drugs may put such therapy out of reach for many patients in need. This new section of the guidance will examine the cost-effectiveness of treatment to help clinicians advise and educate their patients, which is the purpose of the guidance. The new section will not, however, make recommendations regarding the pricing of these therapies for the treatment of HCV. We remain hopeful that the various stakeholders can work together to maximize patient access to optimal care. The development of this cost effectiveness analysis has been initiated and the section will be released as expeditiously as feasible.